Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)’s share price traded down 1.2% during mid-day trading on Monday . The stock traded as low as $60.14 and last traded at $61.33, with a volume of 176,639 shares changing hands. The stock had previously closed at $62.05.

Several equities analysts have recently issued reports on the company. Mizuho upped their price target on Eagle Pharmaceuticals from $47.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday. TheStreet upgraded Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, July 22nd. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $78.00 price objective on shares of Eagle Pharmaceuticals in a report on Monday, June 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $91.94.

The stock has a 50 day moving average of $47.31 and a 200 day moving average of $47.79. The firm has a market capitalization of $958.96 million and a P/E ratio of 314.51.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.09. During the same period last year, the business earned ($0.53) EPS. The firm had revenue of $40.90 million for the quarter, compared to analyst estimates of $43.55 million. The company’s revenue was up 581.7% compared to the same quarter last year. Analysts predict that Eagle Pharmaceuticals Inc. will post $3.34 EPS for the current fiscal year.

An institutional investor recently raised its position in Eagle Pharmaceuticals stock. Bank of Montreal Can boosted its stake in shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) by 62.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 119,902 shares of the specialty pharmaceutical company’s stock after buying an additional 46,020 shares during the period. Bank of Montreal Can owned 0.77% of Eagle Pharmaceuticals worth $10,632,000 as of its most recent filing with the SEC.

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.